GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Crescita Therapeutics Inc (OTCPK:CRRTF) » Definitions » 3-Year FCF Growth Rate

Crescita Therapeutics (Crescita Therapeutics) 3-Year FCF Growth Rate

: -28.70% (As of Dec. 2023)
View and export this data going back to 2016. Start your Free Trial

Crescita Therapeutics's Free Cash Flow per Share for the three months ended in Dec. 2023 was $-0.01.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was -28.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.

During the past 10 years, the highest 3-Year average Free Cash Flow per Share Growth Rate of Crescita Therapeutics was 59.30% per year. The lowest was -28.70% per year. And the median was 5.35% per year.


Competitive Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Crescita Therapeutics's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Crescita Therapeutics 3-Year FCF Growth Rate Distribution

For the Drug Manufacturers industry and Healthcare sector, Crescita Therapeutics's 3-Year FCF Growth Rate distribution charts can be found below:

* The bar in red indicates where Crescita Therapeutics's 3-Year FCF Growth Rate falls into.



Crescita Therapeutics 3-Year FCF Growth Rate Calculation

This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.


Crescita Therapeutics  (OTCPK:CRRTF) 3-Year FCF Growth Rate Explanation

Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.


Crescita Therapeutics 3-Year FCF Growth Rate Related Terms

Thank you for viewing the detailed overview of Crescita Therapeutics's 3-Year FCF Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Crescita Therapeutics (Crescita Therapeutics) Business Description

Traded in Other Exchanges
Address
2805, Place Louis-R-Renaud, Laval, QC, CAN, H7V 0A3
Crescita Therapeutics Inc is a Canadian commercial dermatology company with in-house research & development and manufacturing capabilities. The company offers a portfolio of non-prescription skincare products and early to commercial-stage prescription drug products and owns multiple proprietary drug delivery platforms that support the development of patented formulations that can facilitate the delivery of active ingredients into or through the skin. The company has three reportable segments: Commercial Skincare, Licensing and Royalties, and Manufacturing and Services. The firm generates its revenue in the form of product sales and out-licensing revenue.

Crescita Therapeutics (Crescita Therapeutics) Headlines